Pharmacogenetics in Type 2 Diabetes: Polymorphisms in Candidate Genes Affecting Responses to Antidiabetic Oral Treatment

Publisher： Bentham Science Publishers

E-ISSN： 1875-6204|4|1|69-78

ISSN： 1570-1603

Source： Current Pharmacogenomics, Vol.4, Iss.1, 2006-03, pp. : 69-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus

By Krentz Andrew J.  

Drugs, Vol. 65, Iss. 3, 2005-01 ,pp. : 385-411

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

By  

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus

By Ward Alexandra   O’Brien Judith A   Salas Maribel  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 601-608

Informa Healthcare

Access to resources Recommend Favorite

Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses

By Hung Chin-Chuan   Jen Tai John   Kao Pi-Ju   Lin Min-Shung   Liou Horng-Huei  

Pharmacogenomics, Vol. 8, Iss. 9, 2007-09 ,pp. : 1151-1158

Future Medicine

Access to resources Recommend Favorite

SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?

By Tönjes Anke   Kovacs Peter  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 825-833

Future Medicine

Access to resources Recommend Favorite